Page 1145 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 63 Myelodysplastic Syndromes and Myeloproliferative Neoplasms in Children 1004.e7

276. Prchal JF, Axelrad AA: Letter: bone-marrow responses in polycythemia 286. “Leukemia and Hematosarcoma” Cooperative Group, European
vera. N Engl J Med 290:1382, 1974. Organization for Research on Treatment of Cancer: Treatment of
277. Michiels JJ, Juvonen E: Proposal for revised diagnostic criteria of essen- polycythaemia vera by radiophosphorus or busulphan: a randomized
tial thrombocythemia and polycythemia vera by the Thrombocythemia trial. Br J Cancer 44:75, 1981.
Vera Study Group. Semin Thromb Hemost 23:339, 1997. 287. Higuchi T, Okada S, Mori H, et al: Leukemic transformation of
278. Giona F, Teofili L, Moleti ML, et al: Thrombocythemia and polycythe- polycythemia vera and essential thrombocythemia possibly associated
mia in patients younger than 20 years at diagnosis: clinical and biologic with an alkylating agent. Cancer 75:471, 1995.
features, treatment, and long-term outcome. Blood 119:2219, 2012. 288. Petitt RM, Silverstein MN, Petrone ME: Anagrelide for control of
279. Tefferi A, Thiele J, Orazi A, et al: Proposals and rationale for revision thrombocythemia in polycythemia and other myeloproliferative disor-
of the World Health Organization diagnostic criteria for polycythe- ders. Semin Hematol 34:51, 1997.
mia vera, essential thrombocythemia, and primary myelofibrosis: 289. Silver RT: Imatinib mesylate (Gleevec[TM]) reduces phlebotomy
recommendations from an ad hoc international expert panel. Blood requirements in polycythemia vera. Leukemia 17:1186, 2003.
110:1092, 2007. 290. Donovan PB, Kaplan ME, Goldberg JD, et al: Treatment of polycythe-
280. Cario H, McMullin MF, Pahl HL: Clinical and hematological presenta- mia vera with hydroxyurea. Am J Hematol 17:329, 1984.
tion of children and adolescents with polycythemia vera. Ann Hematol 291. Harman JB, Ledlie EM: Survival of polycythaemia vera patients treated
88:713, 2009. with radioactive phosphorus. Br Med J 2:146, 1967.
281. Tefferi A, Thiele J, Vannucchi AM, et al: An overview on CALR and 292. Castello G, Lerza R, Cerruti A, et al: The in vitro and in vivo effect of
CSF3R mutations and a proposal for revision of WHO diagnostic recombinant interferon alpha-2a on circulating haemopoietic progeni-
criteria for myeloproliferative neoplasms. Leukemia 28:1407, 2014. tors in polycythaemia vera. Br J Haematol 87:621, 1994.
282. Berk PD, Wasserman LR, Fruchtman S, et al: Treatment of polycythe- 293. McMullin MF, Bareford D, Campbell P, et al: Guidelines for the diag-
mia vera, a summary of clinical trends conducted by the polycythemia nosis, investigation and management of polycythaemia/erythrocytosis.
vera sub-group. In Wasserman LPBP, editor: Treatment of polycythemia Br J Haematol 130:174, 2005.
vera, a summary of clinical trends conducted by the Polycythemia Vera Study 294. Marchioli R, Finazzi G, Specchia G, et al: Cardiovascular events and
Group, Philadelphia, 1995, W.B. Saunders, p 166. intensity of treatment in polycythemia vera. N Engl J Med 368:22,
283. Logue GL, Gutterman JU, McGinn TG, et al: Melphalan therapy of 2013.
polycythemia vera. Blood 36:70, 1970. 295. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al: Ruxolitinib versus
284. Milligan DW, Thein SL, Roberts BE: Secondary treatment of polycy- standard therapy for the treatment of polycythemia vera. N Engl J Med
themia rubra vera with 6-thioguanine. Cancer 50:836, 1982. 372:426, 2015.
285. Toh BT, Gregory SA, Knospe WH: Acute leukemia following treat-
ment of polycythemia vera and essential thrombocythemia with uracil
mustard. Am J Hematol 28:58, 1988.